The EPS miss and declining revenue reflect near-term headwinds from lumpy collaboration income, but the pipeline advancement in bexobrutideg remains key. Monitor upcoming Phase 2 enrollment data and IND filing for the tablet formulation as catalysts for sentiment reversal.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $15.60entry
- T+1 · 7mo ago +4.10%α +3.53% · $16.24
- T+5 · 7mo ago +8.78%α +5.27% · $16.97
- T+20 · 7mo ago +6.41%α −2.13% · $16.60
- T+60 · 4mo ago +53.65%α +43.20% · $23.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, and a net loss of $87.2M ($0.79 per share), missing EPS consensus of $-0.73. The miss was driven by lower collaboration revenue as the Sanofi research term wound down, while R&D spending increased to advance bexobrutideg into pivotal trials.
Key Financial Metrics
Key Facts
- Q1 2026 revenue was $6.3M, down from $18.5M in Q1 2025, primarily due to reduced Sanofi collaboration revenue
- EPS of $-0.79 missed consensus of $-0.73 by 7.7%, reflecting higher R&D spend
- R&D expenses rose to $84.1M from $69.7M YoY due to clinical and manufacturing costs for bexobrutideg
- Cash balance was $540.7M as of February 28, 2026, with no near-term liquidity concerns
- Company advancing bexobrutideg in pivotal Phase 2 and planned Phase 3 trials for CLL, with tablet formulation IND targeted in 2026
Financial Impact
Revenue down 66% YoY, EPS miss of 7.7% vs consensus, driven by lower collaboration income and higher R&D spend
Risk Factors
- Dependence on lumpy collaboration revenue creates volatility in financial results
- High R&D spend increases cash burn, though current cash runway appears sufficient
- Clinical trial delays or safety issues in bexobrutideg could negatively impact valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269913 |
Track record
33 reports on NRIX
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers